In vitro safety pharmacology profiling: What else beyond hERG?

Future Medicinal Chemistry

Volumn 1, Issue 4, 2009, Pages 645-665

  Hamon, Jacques ^a   Whitebread, Steven ^b   Techer Etienne, Valerie ^a   Coq, Helene Le ^a   Azzaoui, Kamal ^a   Urban, Laszlo ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC ALPHA1A RECEPTOR; ADRENERGIC ALPHA2A RECEPTOR; ADRENERGIC BETA1 RECEPTOR; ADRENERGIC BETA2 RECEPTOR; ALIZAPRIDE; ALPHA ADRENERGIC RECEPTOR; AMTHAMINE; BETA ADRENERGIC RECEPTOR; BROMOCRIPTINE; CABERGOLINE; CARBACHOL; CLEBOPRIDE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ECOPIPAM; FENOLDOPAM MESILATE; GUANIDINE DERIVATIVE; IMPROMIDINE; ION CHANNEL; LISURIDE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PERGOLIDE; PHENYLPYRIDYLALKYLGUANIDINE DERIVATIVE; PILOCARPINE; POTASSIUM CHANNEL HERG; RANITIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOHIMBINE;

ANXIETY DISORDER; BRADYCARDIA; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DEPRESSION; DIARRHEA; DRUG ACTIVITY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG WITHDRAWAL; DYSTONIA; FEVER; GASTROINTESTINAL DISEASE; HUMAN; HYPERPROLACTINEMIA; HYPOTENSION; IN VITRO STUDY; MUCUS SECRETION; NONHUMAN; OBESITY; OPEN ANGLE GLAUCOMA; PARKINSON DISEASE; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SALIVATION; SALIVATION DISORDER; SCHIZOPHRENIA; SIDE EFFECT; SUICIDAL IDEATION;

DRUG EVALUATION, PRECLINICAL; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; TOXICITY TESTS;

EID: 77953409482     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.51     Document Type: Review

References (72)

1. Whitebread S, Hamon J, Bojanic et al. In vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov. Today 10(21), 1421-1433 (2005).
2. Schuster D, Laggner C, Langer T. Why drugs fail - a study on side effects in new chemical entities. Curr. Pharm. Des. 11, 3545-3559 (2005).
3. Redfern WS, Carlsson L, Davis AS et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsades de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45 (2003).
4. Lagrutta AA, Trepakova ES, Salata JJ. The hERG channel and risk of drug-acquired cardiac arrhythmia: an overview. Curr. Top. Med. Chem. 8(13), 1102-1112 (2008).
5. Wise A, Gearing K, Rees S. Target validation of G-protein coupled receptors. Drug Discov. Today 7(4), 235-246 (2002).
6. Krejsa CM, Horvath D, Rogalski SL et al. Predicting ADME properties and side effects: the bioprint approach. Curr. Opin. Drug Discov. Develop. 6(4), 470-480 (2003).
7. Whitebread S, Hamon J, Scheiber J et al. Broad-scale in vitro pharmacology profiling to predict clinical adverse effects. Am. Drug Discov. 3(2), 32-38 (2008).
8. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J. Recept. Signal Transduct. Res. 24, 165-205 (2004).
9. Zhang A, Neumeyer JL, Baldessarini RJ. Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders. Chem. Rev. 107(1), 274-302 (2007).
10. Santini E, Valjent E, Fisone G. Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J. 275(7), 1392-1399 (2008).
11. Jutkiewicz EM, Bergman J. Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1/D2 interactions. J. Pharmacol. Exp. Ther. 311(3), 1008-1015 (2004).
12. Zeng C, Zhang M, Asico LD et al. The dopaminergic system in hypertension. Clin. Sci. 112, 583-597 (2007).
13. Banday AA, Lokhandwala MF. Dopamine receptors and hypertension. Curr. Hypertens. Rep. 10(4), 268-275 (2008).
14. Oliver WC, Nuttall GA, Cherry KJ et al. A comparison of fenoldopam with dopamine and sodium nitroprusside in patients undergoing cross-clamping of the abdominal aorta. Anesth. Analg. 103(4), 833-840 (2006).
15. Astrup A, Greenway FL, Ling W et al. Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects. Obesity 15(7), 1717-1731 (2007).
16. Tonini M, Cipollina L, Poluzzi E et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment. Pharmacol. Ther. 19(4), 379-390 (2004).
17. Dodd ML, Klos KJ, Bower JH et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch. Neurol. 62(9), 1377-1381 (2005).
18. Parsons ME, Ganellin CR. Histamine and its receptors. Br. J. Pharmacol. 147(1 Suppl.), S127-S135 (2006).
19. Michelotti GA, Price DT, Schwin DA. a1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol. Ther. 88(3), 281-309 (2000).
20. Farkas AS, Acsai K, Toth A et al. Importance of extracardiac a1-adrenoceptor stimulation in assisting dofetilide to induce torsade de pointes in rabbit hearts. Eur. J. Pharmacol. 537(1-3), 118-125 (2006).
21. Lowe FC. Role of the newer a,a-adrenergicreceptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin. Ther. 26(11), 1701-1713 (2004).
22. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol. Rev. 53, 319-356 (2001).
23. Galeotti N, Bartolini A, Ghelardini C. a-2 agonist-induced memory impairment is mediated by the a-2A-adrenoceptor subtype. Behav. Brain Res. 153(2), 409-417 (2004).
24. Park YM, Chung YC, Lee SH et al. Weight gain associated with the a2A-adrenergic receptor - 1,291 C/G polymorphism and olanzapine treatment. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141(4), 394-397 (2006).
25. Fülöp K, Zádori Z, Rónai AZ et al. Characterisation of a2-adrenoceptor subtypes involved in gastric emptying, gastric motility and gastric mucosal defence. Eur. J. Pharmacol. 528(1-3), 150-157 (2005).
26. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557), 201-207 (2007).
27. Cazzola M, Matera MG, Donner CF. Inhaled b2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 65(12), 1595-1610 (2005).
28. Scarpedo HM, Dmochowski RR. Muscarinic receptors: what we know. Curr. Urol. Rep. 4, 421-428 (2003).
29. Fisher A, Pittel Z, Haring R et al. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J. Mol. Neurosci. 20, 349-356 (2003).
30. Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin. Ther. 27(1), 127-138 (2005).
31. Abrams P, Andersson KE, Buccafusco JJ et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br. J. Pharmacol. 148(5), 565-578 (2006).
32. Froloff N, Hamon V, Dupuis P et al. Construction of a homogeneous and informative in vitro profiling database for anticipating the clinical effects of drugs (Chapter 10). In: Chemogenomics - Knowledge-Based Approaches to Drug Discovery. Imperial College Press, London, UK (2006).
33. Jooste E, Zhang Y, Emala CW. Rapacuronium preferentially antagonizes the function of M2 versus M3 muscarinic receptors in guinea pig airway smooth muscle. Anesthesiology 102(1), 117-124 (2005).
34. Hoyer D, Hannon JP, Martin GR. Molecular pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71, 533-554 (2002).
35. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin. Drug Saf. 7(5), 587-596 (2008). Describes the importance of 5-HT2A receptor activation in the genesis of this syndrome.
36. Roth BL. Drugs and valvular heart disease. N. Engl. J. Med. 356(1), 6-9 (2007).
37. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 6(9), 826-829 (2007).
38. Zanettini R, Antonini A, Gatto G et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356, 39-46 (2007).
39. Schade R, Anderson F, Suissa S et al. Dopamine agonists and the risk of cardiac valve regurgitation. N. Engl. J. Med. 356, 29-38 (2007).
40. Horvath J, Fross RD, Kleiner-Fisman G et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord. 19(6), 656-662 (2004).
41. Hofmann C, Penner U, Dorow R et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin. Neuropharmacol. 29(2), 80-86 (2006).
42. Wacker DA, Miller KJ. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases. Curr. Opin. Drug Discov. Devel. 11(4), 438-445 (2008).
43. Miller DD, Ellingrod VL, Holman TL et al. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 133B(1), 97-100 (2005).
44. Wigglesworth MJ, Lawless KJ, Standing DJ et al. Use of cryopreserved cells for enabling greater flexibility in compound profiling. J. Biomol. Screen. 13(5), 354-362 (2008).
45. Rothman RB, Baumann MH. Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol. Ther. 95(1), 73-88 (2002).
46. Levy RJ. Serotonin transporter mechanisms and cardiac disease. Circulation 113(1), 81-89 (2006).
47. Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease. Toxicol. Appl. Pharmacol. 204(3), 355-360 (2005).
48. Kahlig KM, Galli A. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine Eur. J. Pharmacol. 479, 153-158 (2003).
49. Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today 10(22), 1503-1519 (2005).
50. Spina D. PDE4 inhibitors: current status. Br. J. Pharmacol. 155, 308-315 (2008).
51. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365(9454), 167-175 (2005).
52. Osadchii OE. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. Cardiovasc. Drugs Ther. 21(3), 135-139 (2007).
53. Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr. Med. Chem. 11, 2033-2043 (2004).
54. Gentili F, Pizzinat N, Ordener C et al. 3-5-(4.5-Dihydro-1H-imidazol-2- ylphenylamine (Amifuraline), a promising reversible and selective peripheral MAO-A inhibitor. J. Med. Chem. 49, 5578-5586 (2006).
55. Youdim MBH, Weinstock M. Therapeutic applications of selective and non selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology 25, 243-250 (2004).
56. Valley MP, Zhou W, Hawkins EM et al. A bioluminescent assay for monoamine oxidase activity. Anal. Biochem. 359(2), 238-246 (2006).
57. Sieghart W. GABAA receptors as targets for different classes of drugs. Drugs Future 31(8), 685-694 (2006).
58. Korpi ER, Sinkkonen ST. GABAA receptor subtypes as targets for neuropsychiatric drug development. Pharmacol. Ther. 109(1-2), 12-32 (2006).
59. Ebert B, Anderson NJ, Cremers TI et al. Gaboxadol, a different hypnotic profile with no tolerance to sleep EEG and sedative effects after repeated daily dosing. Pharmacol. Biochem. Behav. 90(1), 113-122 (2008).
60. Albensi BC. The NMDA receptor/ion channel complex: a drug target for modulating synaptic plasticity and excitotoxicity. Curr. Pharm. Des. 13(31), 3185-3194 (2007).
61. Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem. 97(6), 1611-1626 (2006).
62. Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modelling schizophrenia. Curr. Opin. Pharmacol. 5(1), 101-106 (2005).
63. Kurkó D, Dezso P, Boros A et al. Inducible expression and pharmacological characterization of recombinant rat NR1A/ NR2A NMDA receptors. Neurochem. Int. 46(5), 369-379 (2005).
64. Houck KA, Kavlock RJ. Understanding mechanisms of toxicity: insights from drug discovery research. Toxicol. Appl. Pharmacol. 227(2), 163-178 (2008).
65. Hamon J, Azzaoui K, Whitebread S et al. In vitro safety pharmacology profiling. Eur. Pharm. Rev. 1, 60-63 (2006).
66. Azzaoui K, Hamon J, Faller B et al. Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2(6), 874-880 (2007).
67. Hughes JD, Blagg J, Price DA, Bailey S et al. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 18(17), 4872-4875 (2008).
68. Verdonk E, Johnson K, McGuinness R et al. Cellular dielectric spectroscopy: a label-free comprehensive platform for functional evaluation of endogenous receptors. Assay Drug Dev. Technol. 4(5), 609-619 (2006).
69. Meyer T, Sartipy P, Blind F et al. New cell models and assays in cardiac safety profiling. Expert Opin. Drug Metab. Toxicol. 3(4), 507-517 (2007).
70. Pouton CW, Haynes JM. Embryonic stem cells as a source of models for drug discovery. Nat. Rev. Drug Disc. 6(8), 605-616 (2007).
71. Barros TP, Alderton WK, Reynolds HM et al. Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br. J. Pharmacol. 154, 1400-1413 (2008).
72. Scheiber J, Chen B, Milik M et al. Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J. Chem. Inf. Model. 49(2), 308-317 (2009).